NO20034324D0 - Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor - Google Patents

Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor

Info

Publication number
NO20034324D0
NO20034324D0 NO20034324A NO20034324A NO20034324D0 NO 20034324 D0 NO20034324 D0 NO 20034324D0 NO 20034324 A NO20034324 A NO 20034324A NO 20034324 A NO20034324 A NO 20034324A NO 20034324 D0 NO20034324 D0 NO 20034324D0
Authority
NO
Norway
Prior art keywords
chemokine receptor
receptor inhibitor
bipiperidinyl derivatives
bipiperidinyl
derivatives
Prior art date
Application number
NO20034324A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034324L (no
Inventor
Rainer Albert
Christian Bruns
Francois Nuninger
Markus Streiff
Gebhard Thoma
Hans-Guenter Zerwes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20034324L publication Critical patent/NO20034324L/no
Publication of NO20034324D0 publication Critical patent/NO20034324D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
NO20034324A 2001-04-09 2003-09-26 Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor NO20034324D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0108876.4A GB0108876D0 (en) 2001-04-09 2001-04-09 Organic Compounds
PCT/EP2002/003871 WO2002081449A1 (en) 2001-04-09 2002-04-08 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors

Publications (2)

Publication Number Publication Date
NO20034324L NO20034324L (no) 2003-09-26
NO20034324D0 true NO20034324D0 (no) 2003-09-26

Family

ID=9912541

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034324A NO20034324D0 (no) 2001-04-09 2003-09-26 Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor

Country Status (27)

Country Link
US (1) US20040142920A1 (ru)
EP (1) EP1379504B1 (ru)
JP (1) JP4366079B2 (ru)
KR (1) KR100616039B1 (ru)
CN (1) CN100469767C (ru)
AR (1) AR035815A1 (ru)
AT (1) ATE446950T1 (ru)
AU (1) AU2002302511B2 (ru)
BR (1) BR0208741A (ru)
CA (1) CA2439241C (ru)
CZ (1) CZ20032723A3 (ru)
DE (1) DE60234167D1 (ru)
EC (1) ECSP034765A (ru)
ES (1) ES2335393T3 (ru)
GB (1) GB0108876D0 (ru)
HU (1) HUP0303724A3 (ru)
IL (1) IL157428A0 (ru)
MX (1) MXPA03009220A (ru)
NO (1) NO20034324D0 (ru)
NZ (1) NZ528712A (ru)
PE (1) PE20021004A1 (ru)
PL (1) PL363011A1 (ru)
PT (1) PT1379504E (ru)
RU (1) RU2296751C2 (ru)
SK (1) SK12422003A3 (ru)
WO (1) WO2002081449A1 (ru)
ZA (1) ZA200306432B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1404667T3 (da) 2001-07-02 2006-07-10 Astrazeneca Ab Piperidinderivater, der er anvendelige som modulatorer af chemokinreceptoraktivitet
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
RU2005110409A (ru) * 2002-10-04 2005-09-10 Юсиби, С.А. (Be) Производные 4-аминопиперидина, способы их получения и использование в качестве медикаментов
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
ES2312856T3 (es) 2002-12-13 2009-03-01 Smithkline Beecham Corporation Compuestos heterociclicos como antagonistas de ccr5.
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
WO2004092136A1 (ja) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその用途
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
BRPI0411414A (pt) * 2003-06-13 2006-07-25 Schering Ag derivados de quinolil amida como antagonistas de cdr-5
US7652142B2 (en) * 2003-11-03 2010-01-26 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
JP2008528477A (ja) * 2005-01-20 2008-07-31 ファイザー・リミテッド 化合物
EP2402316A1 (en) 2005-07-21 2012-01-04 AstraZeneca AB (Publ) Piperidine derivatives
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
WO2008070758A1 (en) * 2006-12-06 2008-06-12 Genzyme Corporation Chemokine receptor binding compounds
WO2010114896A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
MX2013010330A (es) 2011-03-09 2014-11-26 Richard G Pestell Líneas de célula cancerosa de próstata, signaturas de gen, y usos de las mismas.
JP6518585B2 (ja) 2012-05-14 2019-05-22 リチャード ジー． ペステル がんの治療のためのｃｃｒ５の修飾薬の使用
CA2934132A1 (en) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists
US9624199B2 (en) 2013-12-19 2017-04-18 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives
CN105980374A (zh) 2013-12-19 2016-09-28 拜耳制药股份公司 取代的哌啶基四氢喹啉
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
EP0927192B1 (de) * 1996-09-10 2004-05-12 Boehringer Ingelheim Pharma GmbH & Co.KG Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE19637043A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
DE19643331A1 (de) * 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
RU2266281C2 (ru) * 1999-05-04 2005-12-20 Шеринг Корпорейшн Производные пиперидина, фармацевтическая композиция на их основе и способ лечения инфекции вирусом hiv
ES2274793T3 (es) * 1999-06-11 2007-06-01 MERCK & CO., INC. Modulares n-ciclopentilicos de la actividad del receptor de la quimioquina.
CA2413418A1 (en) * 2000-06-21 2001-12-27 Joseph B. Santella Piperidine amides as modulators of chemokine receptor activity
JP2004509108A (ja) * 2000-09-14 2004-03-25 シェーリング　コーポレイション 置換尿素神経ペプチドｙｙ５受容体アンタゴニスト
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PL363011A1 (en) 2004-11-15
CZ20032723A3 (cs) 2003-12-17
KR20030087066A (ko) 2003-11-12
CN100469767C (zh) 2009-03-18
ES2335393T3 (es) 2010-03-26
NO20034324L (no) 2003-09-26
SK12422003A3 (sk) 2004-05-04
MXPA03009220A (es) 2004-01-29
CN1501915A (zh) 2004-06-02
EP1379504A1 (en) 2004-01-14
AU2002302511B2 (en) 2005-08-04
NZ528712A (en) 2005-07-29
EP1379504B1 (en) 2009-10-28
ECSP034765A (es) 2003-10-28
WO2002081449A1 (en) 2002-10-17
JP2004525174A (ja) 2004-08-19
PE20021004A1 (es) 2003-01-03
HUP0303724A3 (en) 2007-09-28
JP4366079B2 (ja) 2009-11-18
RU2003130642A (ru) 2005-04-10
ATE446950T1 (de) 2009-11-15
ZA200306432B (en) 2004-06-04
CA2439241A1 (en) 2002-10-17
HUP0303724A2 (hu) 2004-03-01
IL157428A0 (en) 2004-03-28
RU2296751C2 (ru) 2007-04-10
CA2439241C (en) 2010-06-08
GB0108876D0 (en) 2001-05-30
US20040142920A1 (en) 2004-07-22
AR035815A1 (es) 2004-07-14
DE60234167D1 (de) 2009-12-10
PT1379504E (pt) 2010-01-04
KR100616039B1 (ko) 2006-08-28
BR0208741A (pt) 2004-06-22

Similar Documents

Publication Publication Date Title
NO20034324L (no) Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor
DK1480962T3 (da) 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO20032277L (no) Aminotiazoler og deres anvendelse som adenosinreseptorantagonister
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20031952L (no) 3-aroylinderivater og deres anvendelse som CB2 reseptoragonister
DK1373224T3 (da) Nye spirotricykliske derivater og deres anvendelse som phosphodiesterase 7 inhibitorer
DK1282611T3 (da) Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
DK1373191T3 (da) Acylerede indanylaminer og deres anvendelse som lægemidler
DK1455785T3 (da) Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
NO20032830D0 (no) Tetrahydropyridinderivater, fremstilling derav og anvendelse som celle-proliferasjonsinhibitorer
DK1246802T3 (da) 4-aminopicolinater og deres anvendelse som herbicider
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
NO20053569D0 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som nevrokininantagonister
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
NO20025150L (no) 2-acylindolderivater og deres anvendelse som antitumormidler
NO20043580D0 (no) Quinazolinonderivater og deres bruk som CB agonister
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20034434D0 (no) Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
DK1150996T3 (da) Nye amidinobenzylaminderivater og deres anvendelse som thrombin-inhibitorer
NO20030813D0 (no) Bifenylderivater og deres anvendelse som integrininhibitorer
NO20025884L (no) 2-aminotiazolinderivater og deres anvendelse som NO- syntaseinhibitorer
NO20043799L (no) 2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister
DK1259515T3 (da) Thienopyridinderivater og deres anvendelse som antiinflammatoriske midler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application